Qian Wang

Qian joined Pivotal Bioventure in 2022. Prior to joining Pivotal, Qian was a public equity investor at BlackRock, responsible for investment in biotech and pharmaceutical companies, across multiple therapeutic areas, including oncology, immunology, gene therapy/gene editing, ophthalmology, rare diseases and neuroscience. During the three years spent at BlackRock, Qian helped turned over the biopharma portfolio and pitched multiple companies that were acquired by pharmaceutical companies. Before joining BlackRock, Qian was an equity research analyst at Bank of America Merrill Lynch covering large and SMid cap biotech stocks. She was active in facilitating companies for initial public offerings and secondary raise. Qian received her Ph.D. In molecular biology from University of Maryland at College Park and Bachelor of Science in biotechnology from Fudan University in China.